2.1. Study Setting
SECONDARY, PULMONARY HYPERTENSION
A randomized, double-blind, placebo-controlled, prospective clinical trial was carried out between 9 June 2020 and 12 February 2022 in the intensive care departments of three hospitals in Kyiv, Ukraine: City Clinical Hospital NO. 4, and two multi-profile commercial hospitals, “Manufaktura” and “Raiering”. The study was conducted on random Kyiv City inhabitants (caucasian). Patients with severe COVID-19 and pulmonary hypertension were randomly assigned to receive either sildenafil or a placebo. The primary endpoint was the mortality rate; secondary endpoints were the intubation rate and the duration of ICU stay.